

BIOLIFE SOLUTIONS INC  
Form 8-K  
May 19, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**May 18, 2016**

Date of report (Date of earliest event reported)

**BIOLIFE SOLUTIONS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**                                      **001-36362**                                      **94-3076866**  
(State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)

**3303 Monte Villa Parkway, Bothell, WA 98021**

(Address of principal executive offices, including zip code)

**(425) 402-1400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 18, 2016, BioLife Solutions, Inc. issued the press release entitled “BioLife Solutions Appoints Jim Mathers as New Vice President of Sales.” The press release is attached hereto as Exhibit 99.1. The information contained in the press release attached hereto is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description**

99.1 Press release dated May 18, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 18, 2016 BIOLIFE SOLUTIONS,  
INC.

By: /s/ Roderick de Greef  
Roderick de Greef  
Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press release dated May 18, 2016